Novel cancer immunotherapy agents with survival benefit: recent successes and next steps (original) (raw)

• Burnet, F. M. Immunological aspects of malignant disease. Lancet 1, 1171–1174 (1967).
  Article CAS PubMed Google Scholar
• Burnet, F. M. The concept of immunological surveillance. Prog. Exp. Tumor Res. 13, 1–27 (1970).
  Article CAS PubMed Google Scholar
• Thomas, L. On immunosurveillance in human cancer. Yale J. Biol. Med. 55, 329–333 (1982).
  CAS PubMed PubMed Central Google Scholar
• Kaplan, D. H. et al. Demonstration of an interferon-γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl Acad. Sci. USA 95, 7556–7561 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Shankaran, V. et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107–1111 (2001).
  Article CAS PubMed Google Scholar
• Lasaro, M. O. & Ertl, H. C. Targeting inhibitory pathways in cancer immunotherapy. Curr. Opin. Immunol. 22, 385–390 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Schreibelt, G. et al. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol. Immunother. 59, 1573–1582 (2010).
  Article CAS PubMed Google Scholar
• Speiser, D. E. & Romero, P. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. Semin. Immunol. 22, 144–154 (2010).
  Article CAS PubMed Google Scholar
• Rosenberg, S. A. & Dudley, M. E. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol. 21, 233–240 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Dudley, M. E. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850–854 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Fyfe, G. et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13, 688–696 (1995).
  Article CAS PubMed Google Scholar
• Robbins, P. F. et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917–924 (2011).
  Article PubMed PubMed Central Google Scholar
• Kershaw, M. H. et al. A phase I study of adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106–6115 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Morgan, R. A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126–129 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725–733 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Schwartzentruber, D. et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 364, 2119–2127 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422 (2010).
  Article CAS PubMed Google Scholar
• Kantoff, P. W. et al. Overall survival analysis of a phase II randomized controlled trial of a proxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28, 1099–1105 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA4 blockade. Science 271, 1734–1736 (1996).
  Article CAS PubMed Google Scholar
• Van Elsas, A., Hurwitz, A. A. & Allison, J. P. Combination immunotherapy of B16 melanoma using anti-cytotoxic lymphocyte-associated antigen 4 (CTLA4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190, 355–366 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Quezada, S. A. et al. CTLA4-blockade and GMCSF combination immunotherapy alters the intra-tumor balance of effector and regulatory T cells. J. Clin. Invest. 116, 1935–1945 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Kirkwood, J. M. et al. Phase II trial of tremelimumab (CP675206) in patients with advanced refractory or relapsed melanoma. Clin. Cancer Res. 16, 1042–1048 (2010).
  Article CAS PubMed Google Scholar
• Camacho, L. H. et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J. Clin. Oncol. 27, 1075–1081 (2009).
  Article CAS PubMed Google Scholar
• Ribas, A. Clinical development of the anti-CTLA4 antibody tremelimumab. Semin. Oncol. 37, 450–454 (2010).
  Article CAS PubMed Google Scholar
• Marshall, M. A., Ribas, A. & Huang, B. Evaluation of baseline serum C-reactive protein (CRP) and benefit from tremelimumab compared to chemotherapy in first-line melanoma. J. Clin. Oncol. 28 (Suppl.), Abstract 2609 (2010).
  Article Google Scholar
• Liakou, C. I. et al. CTLA4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc. Natl Acad. Sci. USA 105, 14987–14992 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Chen, H. et al. Anti-CTLA4 therapy results in higher CD4+ICOShi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues. Proc. Natl Acad. Sci. USA 106, 2729–2734 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Carthon, B. C. et al. Preoperative CTLA4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin. Cancer Res. 16, 2861–2871 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Vonderheide, R. H. et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin. Cancer Res. 16, 3485–3494 (2010).
  Article CAS PubMed Google Scholar
• Yuan, J. et al. CTLA4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl Acad. Sci. USA 105, 20410–20415 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Peggs, K. S., Quezada, S. A., Sharma, P. & Allison, J. P. Cancer immunotherapy. In Cancer Medicine 8th edn 175–189 (People's Medical Publishing House, Shelton, Connecticut, 2010).
  Google Scholar
• Wolchok, J. D. et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 11, 155–164 (2010).
  Article CAS PubMed Google Scholar
• Salgaller, M., Marincola, F., Cormier, J. & Rosenberg, S. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res. 56, 4749–4757 (1996).
  CAS PubMed Google Scholar
• Korn, E. L. et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J. Clin. Oncol. 26, 527–534 (2008).
  Article PubMed Google Scholar
• Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517–2526 (2011).
  Article CAS PubMed Google Scholar
• Sznol, M. et al. Safety and antitumor activity of biweekly MDX1106 (Anti-PD1, BMS936558/ONO4538) in patients with advanced refractory malignancies. J. Clin. Oncol. 28 (Suppl.), Abstract 2506 (2010).
  Article Google Scholar
• Saenger, Y. M. & Wolchok, J. D. The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun. 8, 1 (2008).
  PubMed PubMed Central Google Scholar
• O'Day, S. et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann. Oncol. 21, 1712–1717 (2010).
  Article CAS PubMed Google Scholar
• Wolchok, J. D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412–7420 (2009).
  Article CAS PubMed Google Scholar
• Kane, R. C. et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin. Cancer Res. 12, 7271–7278 (2006).
  Article CAS PubMed Google Scholar
• Spira, D. et al. Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. Acad. Radiol. 18, 89–96 (2010).
  Article PubMed Google Scholar
• Suzuki, C. et al. Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics 28, 329–344 (2008).
  Article PubMed Google Scholar
• Gajewski, T. F., Louahed, J. & Brichard, V. G. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J. 16, 399–403 (2010).
  Article CAS PubMed Google Scholar
• Haining, W. N. & Wherry, E. J. Integrating genomic signatures for immunologic discovery. Immunity 32, 152–161 (2010).
  Article CAS PubMed Google Scholar
• Kirkwood, J. M. et al. Immunogenicity and antitumor effects of vaccination with peptide vaccine +/− granulocyte-monocyte colony-stimulating factor and/or IFNα2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin. Cancer Res. 15, 1443–1451 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Slingluff, C. L. et al. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin. Cancer Res. 13, 6386–6395 (2007).
  Article CAS PubMed Google Scholar
• Britten, C. M., Janetzki, S., van der Burg, S. H., Gouttefangeas, C. & Hoos, A. Toward the harmonization of immune monitoring in clinical trials: quo vadis? Cancer Immunol. Immunother. 57, 285–288 (2008).
  Article CAS PubMed Google Scholar
• Janetzki, S. et al. “MIATA”-minimal information about T cell assays. Immunity 31, 527–528 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Janetzki, S., Cox, J. H., Oden, N. & Ferrari, G. Standardization and validation issues of the ELISPOT assay. Methods Mol. Biol. 302, 51–86 (2005).
  CAS PubMed Google Scholar
• Janetzki, S. et al. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol. Immunother. 57, 303–315 (2008).
  Article PubMed Google Scholar
• Moodie, Z. et al. Response definition criteria for ELISPOT assays revisited. Cancer Immunol. Immunother. 59, 1489–1501 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Koup, R. A, Graham, B. S. & Douek, D. C. The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors. Nature Rev. Immunol. 11, 65–70 (2011).
  Article CAS Google Scholar
• Dunn, G. P., Sheehan, K. C., Old, L. J. & Schreiber, R. D. IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res. 65, 3447–3453 (2005).
  Article CAS PubMed Google Scholar
• Dancey, J. E. et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin. Cancer Res. 16, 1745–1755 (2010).
  Article CAS PubMed Google Scholar
• Sjöblom, T. et al. The consensus coding sequences of human breast and colorectal cancers. Science 314, 268–274 (2006).
  Article PubMed Google Scholar
• Segal, N. H. Epitope landscape in breast and colorectal cancer. Cancer Res. 68, 889–892 (2008).
  Article CAS PubMed Google Scholar
• Peggs, K. S., Segal, N. H. & Allison, J. P. Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative. Cancer Cell 12, 192–199 (2007).
  Article CAS PubMed Google Scholar
• Hodi, F. S. et al. A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol. 29 (Suppl.), Abstract 8511 (2011).
  Article Google Scholar
• Ngiow, S. et al. Anti-TIM3 antibody promotes T cell IFNγ-mediated antitumor immunity and suppresses established tumors. Cancer Res. 71, 3540–3551 (2011).
  Article CAS PubMed Google Scholar
• Wang, L. et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J. Exp. Med. 208, 577–592 (2011).
  Article CAS PubMed PubMed Central Google Scholar